Pharmanutra

Transaction in Own Shares • May 16, 2022

Informazione Regolamentata n. 20106-40-2022		Data/Ora Ricezione 16 Maggio 2022 11:35:37	Euronext Star Milan
Societa'	:	PHARMANUTRA
Identificativo Informazione Regolamentata	:	162321
Nome utilizzatore	:	PHARMANUTRAN04 - Roberto Lacorte
Tipologia	:	REGEM
Data/Ora Ricezione	:	16 Maggio 2022 11:35:37
Data/Ora Inizio Diffusione presunta	:	16 Maggio 2022 11:35:38
Oggetto	:	PR - PHARMANUTRA Initiation of share buy-back program
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

Pisa, 16th May 2022 – PharmaNutra S.p.A. (MTA; Ticker PHN), a group of companies specialised in mineral supplements and medical devices for muscles and joints, announces the beginning of a share buyback program, previously authorized by the Shareholders' Meeting of April 27 th, 2022 and by today's Board of Directors.

The program is aimed at allowing the Company to seize the opportunity to make an advantageous investment, in cases where the market price of PHN shares, also due to factors external to the Company, is not able to adequately express the value of the same, and therefore to provide the Company with a useful strategic investment opportunity for all purposes permitted by current regulations.

The purchase of shares within the scope of the programme is done with the modalities and within the operating limits laid down in the decision referred to above, by Article 5 of (EU) Regulation no. 596/2014 (Market Abuse Regulation), by Article 3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 and by the general and industry legislation in force, in particular:

• purchases will be for a maximum overall of 17.742 ordinary shares of the Company without indication of nominal value to a maximum value of EUR 1,100,000;
• such purchases will be made with a consideration that is not higher than the highest price of the last independent operation and the highest current independent bid on the trading venues where the purchase is carried out, it being understood that the price cannot be lower than a minimum of 20% or higher than a maximum of 10% than the stock price registered at the close of the trading session prior to each single purchase transaction;
• such purchases will be made for quantities not exceeding 25% of the average daily volume of PHN shares in the trading venue where the purchase is carried out, calculated on the basis of the average daily volume traded in the 20 trading days prior to the date of purchase;
• the purchase programme will be realized within 18 months from the date of the Shareholders' Meeting of 27 April 2022.

Intermonte SIM S.p.A. operates as an intermediary responsible for purchases within the scope of the programme. The Company will provide information with regard to the transactions relating to the programme for the purchase of own shares, in accordance with the terms and conditions required by the applicable regulation. Any subsequent change to the above-described buy-back plan will be promptly disclosed by the Company. As at the date of this press release, PharmaNutra holds n. 30.121 treasury

shares in portfolio equal to 0.31% of the share capital.

PharmaNutra S.p.A.

Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a wealth of scientific evidence, including 135 publications with over 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 150 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 41 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL®, for which it boasts key patents for the Sucrosomial® Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

PharmaNutra.it

For further details:

Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 investorrelation@PharmaNutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com